Avocado Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.20 M
as on 18-06-2024
- Paid Up Capital ₹ 0.96 M
as on 18-06-2024
- Company Age 15 Year, 6 Days
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.50 M
as on 18-06-2024
- Revenue 49.59%
(FY 2023)
- Profit 82.48%
(FY 2023)
- Ebitda 113.43%
(FY 2023)
- Net Worth 42.57%
(FY 2023)
- Total Assets 36.52%
(FY 2023)
About Avocado Pharmaceuticals
The Corporate was formerly known as Avacado Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.20 M and a paid-up capital of Rs 0.96 M.
The company has closed loans amounting to ₹2.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sumesh Gangadharan, Suresh Pillai, and Kunukkara Manoj serve as directors at the Company.
- CIN/LLPIN
U51397KL2009PTC025181
- Company No.
025181
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Dec 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernad, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Avocado Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kunukkara Manoj  | Managing Director | 01-Feb-2010 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sumesh Gangadharan | Director | 05-Feb-2013 | Current |
| Suresh Pillai | Director | 05-Feb-2013 | Current |
Financial Performance of Avocado Pharmaceuticals.
Avocado Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 49.59% increase. The company also saw a substantial improvement in profitability, with a 82.48% increase in profit. The company's net worth Soared by an impressive increase of 42.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avocado Pharmaceuticals?
In 2023, Avocado Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nance Refreshing Health Care Private LimitedActive 1 year 7 monthsSumesh Gangadharan, Suresh Pillai and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 Feb 2017 | ₹2.50 M | Satisfied |
How Many Employees Work at Avocado Pharmaceuticals?
Unlock and access historical data on people associated with Avocado Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avocado Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avocado Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
